Abstract
In this triple analysis report BioSeeker Group has analyzed three major and
intertwined areas of cancer R&D, Antibody drug targets, Melanoma, and NSCLC,
which are all subjects to an extensive number of innovative drug candidates.
This extensive 450+ pages report compiles and analyzes in parallel the
progress concerning drug development and competitive situation in Antibody
drug targeting and further give an in depth analysis in two key oncology
areas; Leukemia and Lymphoma. The report will not only provide a framework but
also a careful identification and evaluation of drug candidates, technologies
and competitors.
There are currently more than 400 antibody based drugs in development for the
treatment of cancer. BioSeeker has surveyed these antibodies and identified
132 antibody drug targets, belonging to 220 antibody drugs. In all they range
from preclinical development to established therapy leaders in the market
place. In total more than 420 clinical trials are included in this analysis,
covering more than 30 different cancer indications plus diagnosis and
supportive care.
Drug targets and their associated antibodies have been analyzed by BioSeeker
according to:
- 34 Different molecular functions of target
- 13 Major signaling pathways
- Cancer stem cells
- Conjugated antibodies
- Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase
Inhibition
- 31 Targeted cancer indications
- Availability of expression profiles of targets in human tissues, cancer
tissues, established cell lines and primary cell cultures
- Antibody therapeutic companies
The risk of malignant melanoma has more than doubled in the past decade. The
incidence of melanoma is rising faster than that of any other cancer. This
in-depth analysis of the progress of melanoma R&D and current treatment
strategies is one of the most extensive reports available in this field. No
less than 68 approved drugs and drug candidates have been studied. Progress
profiles and structured information will allow you to pin-point your
knowledge-base in a most cost-effective way. New interesting phase III studies
have been initiated. By gathering information around most drugs under
development for melanoma and specially the late stage pipeline it has been
clear that four major therapeutic strategies generated the most interesting
data.
Lung cancer is the third most common malignant disease and the first leading
cause of cancer death in the western world. Yet platinum agent constitutes the
current mainstay of front-line metastatic lung cancer treatment. There are
currently two platinum-based compounds that are marketed and clinically used
worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs
are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build
the first-line treatment options. Several different studies have been or are
comparing different combinations of these drugs. Lately gefitinib, pemetrexed
and erlotinib have entered the market and are initially used in second or
third-line treatments. In this report we are not only describing the progress
of different combinations of approved drugs but as well the progress of 21
late stage drug candidates are described and analyzed. Progress profiles and
structured information will allow you to pin-point your knowledge-base in a
most cost effective way. By gathering information around most drugs under
development for lung cancer and specially the late stage pipeline it is has
been clear that four major therapeutic strategies generated most interesting
data. With this report you will be able to track down and foresee activities
associated with the development of new treatments for lung cancer. According
to market analytical studies, the NSCLC drug market is predicted to exceed $4
billion between 2010 and 2015. Chemotherapy drugs will experience generic
erosion and three major chemotherapy drugs go off patent before 2012; Aventis'
Taxotere (docetaxel), Bristol-Myers Squibb' s Paraplatin (carboplatin) and Eli
Lilly' s Gemzar (gemcitabine).
View Cart
